LinusBio Raises $8 Million To Scale Production Of StrandDx Early Autism Diagnostic Test

Linus Biotechnology Inc. (LinusBio) raised $8 million in investor funding in a partnership with Y.A.C. Holdings, a Japanese multinational. LinusBio intends to use the investment to build international partnerships and scale production of its early autism diagnostic test—StrandDx™ASD—anticipated to launch publicly in 2024. The StrandDx™ASD test has been granted an FDA Breakthrough Designation and is on track to become available to the public as a laboratory developed test (LDT) by the first half of 2024. The test can assess the likelihood of autism at birth with 80% to 90% accuracy. In preparation for the . . .